ENL links histone acetylation to oncogenic gene expression in acute myeloid leukaemia (original) (raw)

Accession codes

Primary accessions

Gene Expression Omnibus

Protein Data Bank

References

  1. Garraway, L. A. & Lander, E. S. Lessons from the cancer genome. Cell 153, 17–37 (2013)
    Article CAS Google Scholar
  2. Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067–1073 (2010)
    Article ADS CAS Google Scholar
  3. Dawson, M. A. et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478, 529–533 (2011)
    Article ADS CAS Google Scholar
  4. Li, Y. et al. AF9 YEATS domain links histone acetylation to DOT1L-mediated H3K79 methylation. Cell 159, 558–571 (2014)
    Article CAS Google Scholar
  5. Deshpande, A. J., Bradner, J. & Armstrong, S. A. Chromatin modifications as therapeutic targets in MLL-rearranged leukemia. Trends Immunol. 33, 563–570 (2012)
    Article CAS Google Scholar
  6. Somervaille, T. C. P. et al. Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell 4, 129–140 (2009)
    Article CAS Google Scholar
  7. Lin, C. et al. AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol. Cell 37, 429–437 (2010)
    Article CAS Google Scholar
  8. He, N. et al. Human Polymerase-Associated Factor complex (PAFc) connects the Super Elongation Complex (SEC) to RNA polymerase II on chromatin. Proc. Natl Acad. Sci. USA 108, E636–E645 (2011)
    Article CAS Google Scholar
  9. Yokoyama, A., Lin, M., Naresh, A., Kitabayashi, I. & Cleary, M. L. A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. Cancer Cell 17, 198–212 (2010)
    Article CAS Google Scholar
  10. Kawahara, M. et al. H2.0-like homeobox regulates early hematopoiesis and promotes acute myeloid leukemia. Cancer Cell 22, 194–208 (2012)
    Article CAS Google Scholar
  11. Sims, R. J. III, Belotserkovskaya, R. & Reinberg, D. Elongation by RNA polymerase II: the short and long of it. Genes Dev. 18, 2437–2468 (2004)
    Article CAS Google Scholar
  12. Luo, Z. et al. The super elongation complex family of RNA polymerase II elongation factors: gene target specificity and transcriptional output. Mol. Cell. Biol. 32, 2608–2617 (2012)
    Article CAS Google Scholar
  13. Peterlin, B. M. & Price, D. H. Controlling the elongation phase of transcription with P-TEFb. Mol. Cell 23, 297–305 (2006)
    Article CAS Google Scholar
  14. Filippakopoulos, P. & Knapp, S. Targeting bromodomains: epigenetic readers of lysine acetylation. Nat. Rev. Drug Discov. 13, 337–356 (2014)
    Article CAS Google Scholar
  15. Jang, M. K. et al. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol. Cell 19, 523–534 (2005)
    Article CAS Google Scholar
  16. Rathert, P. et al. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nature 525, 543–547 (2015)
    Article ADS CAS Google Scholar
  17. Fong, C. Y. et al. BET inhibitor resistance emerges from leukaemia stem cells. Nature 525, 538–542 (2015)
    Article ADS CAS Google Scholar
  18. Perlman, E. J. et al. MLLT1 YEATS domain mutations in clinically distinctive Favourable Histology Wilms tumours. Nat. Commun. 6, 10013 (2015)
    Article ADS CAS Google Scholar
  19. Trapnell, C., Pachter, L. & Salzberg, S. L. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25, 1105–1111 (2009)
    Article CAS Google Scholar
  20. Anders, S., Pyl, P. T. & Huber, W. HTSeq—a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166–169 (2015)
    Article CAS Google Scholar
  21. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014)
    Article Google Scholar
  22. Mi, H., Poudel, S., Muruganujan, A., Casagrande, J. T. & Thomas, P. D. PANTHER version 10: expanded protein families and functions, and analysis tools. Nucleic Acids Res. 44 (D1), D336–D342 (2016)
    Article CAS Google Scholar
  23. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005)
    Article ADS CAS Google Scholar
  24. Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137 (2008)
    Article Google Scholar
  25. Wen, H. et al. ZMYND11 links histone H3.3K36me3 to transcription elongation and tumour suppression. Nature 508, 263–268 (2014)
    Article ADS CAS Google Scholar
  26. Bernt, K. M. et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 20, 66–78 (2011)
    Article CAS Google Scholar
  27. Guenther, M. G. et al. Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev. 22, 3403–3408 (2008)
    Article CAS Google Scholar

Download references

Acknowledgements

We thank H. Li, M. Armstrong, C.-W. Chen, M. Yu, H. Chu, K. Tanaka, D. Peng and T. Scott for discussions and technical supports. We are grateful to The Rockefeller University Genomic Resource Center, Flow Cytometry Resource Center, The MD Anderson Science Park Next-Generation Sequencing Facility (CPRIT RP120348), The Sequencing and Microarray Facility and The Flow Cytometry and Cellular Imaging Core Facility (NIH/NCI P30CA016672), The Shanghai Synchrotron Radiation Facility BL17U beamline, and The China National Center for Protein Sciences Beijing for facility supports. The research was supported by funds from NIH (1R01CA204639-01), the Leukaemia and Lymphoma Society (LLS-SCOR 7006-13), and The Rockefeller University to C.D.A.; NIH grants (CA66996 and CA140575) and the Leukaemia and Lymphoma Society to S.A.A.; grants from NIH/NCI (1R01CA204020-01), Cancer Prevention and Research Institute of Texas (RP160237 and RP170285) and Welch Foundation (G1719) to X.S.; grants from the Major State Basic Research Development Program in China (2016YFA0500700 and 2015CB910503), and the Tsinghua University Initiative Scientific Research Program to H.L.; and grants from NIH (R01HG007538 and R01CA193466) to W.L. X.S. is a recipient of a Leukaemia & Lymphoma Society Career Development Award and an R. Lee Clark Fellow and Faculty Scholar of MD Anderson Cancer Center. L.W. is a fellow of the Jane Coffin Childs Memorial Fund. Y.L. is a Tsinghua Advanced Innovation fellow.

Author information

Author notes

  1. Amanda L. Souza & James E. Bradner
    Present address: † Present addresses: Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, USA (A.L.S., J.E.B.).,
  2. Liling Wan, Hong Wen and Yuanyuan Li: These authors contributed equally to this work.
  3. Haitao Li, C. David Allis, Scott A. Armstrong and Xiaobing Shi: These authors jointly supervised this work.

Authors and Affiliations

  1. Laboratory of Chromatin Biology & Epigenetics, The Rockefeller University, New York, 10065, New York, USA
    Liling Wan, Julia K. Joseph & C. David Allis
  2. Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, 10065, New York, USA
    Liling Wan, Takayuki Hoshii & Scott A. Armstrong
  3. Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, 02215, Massachusetts, USA
    Liling Wan, Takayuki Hoshii & Scott A. Armstrong
  4. Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, 77030, Texas, USA
    Hong Wen, Xiaolu Wang & Xiaobing Shi
  5. Center for Cancer Epigenetics, The University of Texas MD Anderson Cancer Center, Houston, 77030, Texas, USA
    Hong Wen & Xiaobing Shi
  6. Department of Basic Medical Sciences, Beijing Advanced Innovation Center for Structural Biology, MOE Key Laboratory of Protein Sciences, School of Medicine, Tsinghua University, Beijing, 100084, China
    Yuanyuan Li & Haitao Li
  7. Tsinghua-Peking Joint Center for Life Sciences, Tsinghua University, Beijing, 100084, China
    Yuanyuan Li & Haitao Li
  8. Department of Molecular and Cellular Biology, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, 77030, Texas, USA
    Jie Lyu, Yuanxin Xi & Wei Li
  9. Fishberg Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, 10029, New York, USA
    Yong-Hwee E. Loh & Li Shen
  10. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 0221, Massachusetts, USA
    Michael A. Erb, Amanda L. Souza & James E. Bradner
  11. Department of Medicine, Harvard Medical School, Boston, 02115, Massachusetts, USA
    James E. Bradner
  12. Genes and Development and Epigenetics & Molecular Carcinogenesis Graduate Programs, The University of Texas Graduate School of Biomedical Sciences, 77030, Texas, Houston, USA
    Xiaobing Shi

Authors

  1. Liling Wan
    You can also search for this author inPubMed Google Scholar
  2. Hong Wen
    You can also search for this author inPubMed Google Scholar
  3. Yuanyuan Li
    You can also search for this author inPubMed Google Scholar
  4. Jie Lyu
    You can also search for this author inPubMed Google Scholar
  5. Yuanxin Xi
    You can also search for this author inPubMed Google Scholar
  6. Takayuki Hoshii
    You can also search for this author inPubMed Google Scholar
  7. Julia K. Joseph
    You can also search for this author inPubMed Google Scholar
  8. Xiaolu Wang
    You can also search for this author inPubMed Google Scholar
  9. Yong-Hwee E. Loh
    You can also search for this author inPubMed Google Scholar
  10. Michael A. Erb
    You can also search for this author inPubMed Google Scholar
  11. Amanda L. Souza
    You can also search for this author inPubMed Google Scholar
  12. James E. Bradner
    You can also search for this author inPubMed Google Scholar
  13. Li Shen
    You can also search for this author inPubMed Google Scholar
  14. Wei Li
    You can also search for this author inPubMed Google Scholar
  15. Haitao Li
    You can also search for this author inPubMed Google Scholar
  16. C. David Allis
    You can also search for this author inPubMed Google Scholar
  17. Scott A. Armstrong
    You can also search for this author inPubMed Google Scholar
  18. Xiaobing Shi
    You can also search for this author inPubMed Google Scholar

Contributions

L.W., H.W., Y.L., H.L., C.D.A., S.A.A. and X.S. designed the study, analysed the data and wrote the paper. L.W. and H.W. planned and performed all the molecular, cellular and genomic studies; Y.L. and H.L. performed structural and calorimetric studies; L.W., T.H., M.A.E., A.L.S. and J.E.B. performed mouse xenograft studies; L.W., J.L., Y.X., Y.-H.E.L., L.S. and W.L. performed bioinformatics analysis; J.K.J. and X.W. provided technical assistance; H.L., C.D.A., S.A.A. and X.S. supervised the research.

Corresponding authors

Correspondence toC. David Allis, Scott A. Armstrong or Xiaobing Shi.

Ethics declarations

Competing interests

C.D.A. is a co-founder of Chroma Therapeutics and Constellation Pharmaceuticals; C.D.A. and X.S. are Scientific Advisory Board members of EpiCypher; S.A.A. is a consultant for Epizyme, Inc.

Additional information

Reviewer Information Nature thanks R. Agami, J. L. Hess, R. Marmorstein and the other anonymous reviewer(s) for their contribution to the peer review of this work.

Extended data figures and tables

Extended Data Figure 1 Depletion of ENL impairs the growth of AML.

a, Western blot demonstrating the knockdown efficiency of five independent sgRNAs (sg1–sg5) targeting ENL. b, Competition assay that plots the relative percentage of RFP+sgRNA+ cells after transduction of leukaemia cells with indicated sgRNAs. n = 3. c, Western blot demonstrating the knockdown efficiency of five independent sgRNAs targeting AF9. d, Competition assay that plots the relative percentage of RFP+sgRNA+ cells after transduction of leukaemia cells with indicated sgRNAs. n = 3. e, Western blot demonstrating the induction of Cas9 expression after Dox treatment in iCas9-MOLM-13 cells. f, Western blot demonstrating the decrease in ENL protein levels upon Dox treatment in iCas9-MOLM-13 cells. g, Competition assay that plots the relative percentage of RFP+sgRNA+ cells after Dox treatment in iCas9-MOLM-13 cells. n = 3. h, Relative ENL mRNA levels determined by quantitative PCR after reverse transcription (qRT–PCR) in MV4;11 cells transduced with non-targeting (NT) control or ENL shRNAs (shENL-1, shENL-2). i, Representative images (left) and quantification (right) of colonies formed by MV4;11 cells transduced with indicated shRNAs. j, Light microscopy of May-Grünwald/Giemsa-stained MV4;11 leukaemia cells transduced with control or ENL shRNAs. k, FACS analysis of CD11b surface expression after 4 days of Dox-induced Cas9 expression (left) and quantification of CD11b median intensity (right) in iCas9-MOLM-13 cells transduced with indicated sgRNAs and rescue constructs. n = 3. l–o, Negative-selection competition assay that plots the relative percentage of RFP+sgRNA+ cells after Dox treatment in iCas9-U-937 (l), iCas9-K562 (m), iCas9-HeLa (n) and iCas9-U2OS (o) cells. n = 3. p–r, LSK cells were sorted from bone marrow of C57BL/6 mice and transduced with luciferase (shLuc) or Enl shRNA (shEnl). p, Relative Enl mRNA levels determined by qRT–PCR quantification after 3 days of drug selection. q, Relative proliferation of control (shLuc) or _Enl_-knockout (shEnl) LSKs. n = 4. r, Quantification of colonies formed by LSK cells cultured for 7 days. n = 4. G, granulocyte; GM, colony-forming unit containing granulocyte and macrophage; M, macrophage. All error bars represent mean ± s.d. See Supplementary Fig. 1 for western blot gel source data.

Extended Data Figure 2 ENL is required for AML growth in vivo.

a, Representative flow cytometry plots of donor-derived (human CD45+) peripheral blood cells 27 or 32 days after transplantation. The gate shown includes RFP+sgRNA+ human leukaemia cells. b, Representative flow cytometry plots of bone marrow cells in terminally diseased mice receiving cells transduced with ENL sgRNA. Most outgrowing leukaemia cells were RFP+sgRNA+. c, Western blot of sorted RFP+sgRNA+ leukaemia cells from terminally diseased mice (n = 3) receiving cells transduced with control or ENL sgRNA. See Supplementary Fig. 1 for western blot gel source data.

Extended Data Figure 3 Depletion of ENL deregulates core cellular processes and oncogenic pathways that are required for AML maintenance.

a–f, RNA for RNA-seq experiments was obtained from sorted RFP+sgRNA+ iCas9-MOLM-13 cells after 3 or 5 days of Dox treatment. a, Venn diagram showing the number and overlap of genes for which expression is significantly changed (adjusted P < 0.05) upon expression of indicated sgRNAs as compared to GFP control. **b**, Dot plots showing a strong correlation of transcriptional changes (log2 fold change over GFP control) caused by two independent sgRNAs targeting _ENL_. _r_, correlation coefficient. **c**, Heat map representation of genes differentially expressed between iCas9-MOLM-13 cells expressing sgRNAs targeting GFP control, _ENL_ or _AF9_ (fold change > 1.5 and adjusted P < 0.05) after 3 days of Dox induction. d, e, GSEA plots evaluating the changes in monocyte differentiation and leukaemia stem cell gene signatures (d) and the MYC pathways (e) upon ENL depletion. f, Gene Ontology (GO) term analyses of downregulated (ENL-KO-DN, top) or upregulated (ENL-KO-UP, bottom) genes in ENL sgRNA-expressing cells. The top five biological processes that each group of genes were enriched in were shown (details in Supplementary Table 2). Fold enrichment and P values are shown. g, h, RNA for RNA-seq experiments was obtained from MV4;11 transduced with non-targeting (NT) or ENL shRNAs. GSEA plots evaluating the changes in monocyte differentiation and leukaemia stem-cell gene signatures (g) and the oncogenic pathways (h) after ENL knockdown.

Extended Data Figure 4 ENL depletion decreases the occupancies of total Pol II and Pol II S2P on ENL-bound genes.

a, b, Venn diagram showing overlaps of Flag–ENL-occupied genes with those of MLL-AF9 in MOLM-13 (ref. 26) (a) or MLL-AF4 in MV4;11 cells (ref. 27) (b), respectively. c, Venn diagram showing overlaps of Flag–ENL-occupied genes in MOLM13, MV4;11 and HeLa cells. See Supplementary Table 7. d, IPA analysis of ENL-bound genes overlapped among leukaemia cells but not HeLa cells. e, Genomic distribution of Flag–ENL ChIP–seq peaks in MV4;11 cells. The peaks are enriched in the promoter regions (TSS ± 3 kb). P < 1 × 10−300 (binomial test). See Supplementary Table 6. f, Average occupancies of Flag–ENL (blue) and Pol II (black) on Flag–ENL-bound genes in MV4;11 cells along the transcription unit. g, Box plots showing the fold changes (normalized to GFP control) of Pol II occupancy at TSS (TSS −30 bp to TSS +300 bp) or the rest of the gene body on ENL-bound and activated genes upon the expression of ENL sgRNA. The fold changes at both TSS and gene body were significantly lower than 1 (P < 0.0001 by one sample, two-tailed Student’s _t_-test). h, The genome browser view of Pol II signals in a few of ENL-bound genes (MYC, HLX, SLC1A5) in cells expressing sgRNAs targeting GFP (red) or ENL (blue). TSS is indicated by an arrow. i, Western blot showing comparable cellular levels of Pol II S2P in MOLM-13 cells expressing sgRNAs targeting GFP or ENL. See Supplementary Fig. 1 for gel source data. j, k, Average H3K79me2 (j) and H3K79me3 (k) occupancy on Flag–ENL-bound or non-ENL-bound genes (others) in cells expressing sgRNAs targeting GFP control or ENL.

Extended Data Figure 5 Binding specificity and detail of H3K27ac-bound ENL YEATS complex.

a, Histone peptide microarray (detailed annotations on the left) probed with anti-GST antibody against GST–ENL YEATS domain. H3K9ac, H3K18ac and H3K27ac are highlighted in yellow boxes. b, LIGPLOT diagrams of H3K27ac-ENL YEATS complex, listing interactions between H3 peptide and ENL YEATS. H3 segments (orange) and key residues of ENL YEATS (blue) are depicted in ball-and-stick mode. Grey ball, carbon; blue ball, nitrogen; red ball, oxygen; large cyan sphere, water molecule. Hydrogen bonds are indicated as green dashed lines with bond length shown in ångströms. Hydrophobic contacts are represented by an arc with spokes radiating towards the ligand atoms they contact, and the contacted atoms are shown with spokes radiating back.

Extended Data Figure 6 The YEATS domain is required for the chromatin localization of ENL.

a, Box plots showing H3K9ac (red) and H3K27ac (green) occupancy in ENL-bound or unbound genes (others) in MOLM-13 cells. P < 8.1 × 10−152 (H3K9ac) and P < 2.2 × 10−136 (H3K27ac) by two-tailed unpaired Student’s _t_-test. b, Venn diagram showing the overlap of Flag–ENL (blue) and H3K27ac ChIP–seq peaks (green) at promoter or enhancer regions. Promoter H3K27ac is defined as H3K27ac peaks at TSS ± 3 kb regions co-occupied with H3K4me3; enhancer H3K27ac is defined as non-promoter H3K27ac peaks co-occupied with H3K4me1. There is a significant overlap between Flag–ENL and H3K27ac ChIP–seq peaks at TSS (P = 5.7 × 10−105, two-way Fisher exact test) but not at enhancer (P = 1.0, two-way Fisher exact test). c, Average genome-wide occupancies of Flag–ENL (blue), H3K9ac (red), H3K27ac (green) at Flag–ENL-bound genes along the transcription unit in MV4;11 cells. See Supplementary Tables 8 and 9. d, Western blot showing the protein levels of ectopically expressed wild-type or mutant Flag–ENL (marked by asterisk) and endogenous ENL (marked by double asterisk). e, The genome browser view of H3K27ac, H3K9ac, Flag–ENL signals in a few of ENL-bound genes (MYC, HLX). TSS is indicated by an arrow. f, Average occupancies of wild-type, F59A or Y78A mutant Flag–ENL on ENL-bound genes along the transcription unit in MV4;11 cells. g, Western blot analysis of co-immunoprecipitation using the M2 anti-Flag antibody in cells expressing Flag–ENL and Myc-tagged DOT1L, AFF4, CDK9 or ELL2 proteins. FL, full-length; ΔN, deletion of amino acids 1–113; ΔC, deletion of amino acids 430–559. h, Western blot analysis of immunoprecipitation using the M2 anti-Flag antibody in cells expressing wild-type or mutant Flag–ENL. Endogenous CDK9 and AFF4 were assessed. i, qPCR analysis of the Pol II ChIP signal in MYC gene in ENL sgRNA-expressing cells rescued by wild-type or mutant (F59A or Y78A) mouse ENL. Error bars represent mean ± s.e.m. *P < 0.5, ***P < 0.001 (two-tailed unpaired Student’s _t_-test). See Supplementary Fig. 1 for gel source data.

Extended Data Figure 7 The YEATS domain-histone acetylation interaction is required for the role of ENL in leukaemias.

a, GSEA plots evaluating the enrichment of signatures related to stem cells, cell cycle or the MYC pathway in the indicated comparisons. b, Quantification of CD11b median intensity 4 days after Dox induction in iCas9-MOLM-13 cells transduced with indicated sgRNAs and rescue constructs. n = 3. ***P < 0.001 by two-tailed unpaired Student’s _t_-test. c, Negative-selection competition assay that plots the relative percentage of RFP+sgRNA+ cells after transduction of leukaemia cells with indicated constructs. n = 3. d, Quantification of CD11b median intensity 6 days after Dox induction in iCas9-MOLM-13 cells transduced with indicated sgRNAs and rescue constructs. n = 3. ***P < 0.001 by two-tailed unpaired Student’s _t_-test. e, Percentage of human CD45+ cells in peripheral blood of mice transplanted with MOLM-13 cells expressing indicated sgRNAs and rescue constructs 30 days after injection (n ≥ 8). ****P < 0.0001 by two-tailed unpaired Student’s _t_-test. All error bars represent mean ± s.d.

Source data

Extended Data Figure 8 Depletion of ENL increases sensitivity to JQ1 by potentiating JQ1-induced transcriptional changes.

a, Effect of JQ1 on the proliferation (normalized to DMSO control) of MOLM-13 cells transduced with indicated sgRNAs targeting SEC components. n = 5. b, Effect of JQ1 on the proliferation of indicated _MLL_-rearranged leukaemia cells transduced with shNT (red) or shENL (blue) shRNAs. (n = 3). c, d, Effect of JQ1 on the proliferation of indicated non-leukaemia cells (U2OS and HeLa) transduced with GFP, AF9 or ENL sgRNAs. n = 5. e, Kaplan–Meier survival curves of mice (n = 10 per group) transplanted with iCas9-MOLM-13 cells expressing indicated sgRNAs and pretreated with doxycycline for 4 days and JQ1 (or DMSO control) for 2 days ex vivo. P values were calculated using a log-rank test. f–i, RNA for RNA-seq experiments was obtained from sorted RFP+sgRNA+ iCas9-MOLM-13 cells treated with DMSO (marked as ‘0’) or 50 nM JQ1 for 24 h. Row-normalized heat map (f and h) and box plots of relative expression levels (_z_-scores, g and i) of genes found to be twofold downregulated (f and g) or upregulated (h and i) after JQ1 treatment in ENL sgRNA-expressing cells. All error bars represent mean ± s.e.m.

Extended Data Table 1 Data collection and refinement statistics

Full size table

Supplementary information

Supplementary Information

This file contains Supplementary Figure 1, uncropped scans with size marker indications. (PDF 1248 kb)

Supplementary Tables

This file contains the following Supplementary Tables: Differentially expressed genes, Gene ontology analysis, ChIP-seq peaks, ChIP-seq occupied genes, and lists of shRNA/sgRNA sequences, oligos, antibodies and GSEA gene sets used in this study. (XLSX 29662 kb)

PowerPoint slides

Source data

Rights and permissions

About this article

Cite this article

Wan, L., Wen, H., Li, Y. et al. ENL links histone acetylation to oncogenic gene expression in acute myeloid leukaemia.Nature 543, 265–269 (2017). https://doi.org/10.1038/nature21687

Download citation